In another study, the researchers evaluated the cost‐effectiveness of 12 first‐line treatments, including osimertinib monotherapy, for patients with advanced EGFR‐mutated NSCLC from the perspectives of the United Kingdom and China.30 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.